A Japanese study by Y. Suzumura titled “Analysis of the Association Between BNT162b2 mRNA COVID-19 Vaccination and Deaths Within 10 Days After Vaccination Using the Sex Ratio in Japan” published on 7 December 2023 has found that the Pfizer vaccine “may influence the occurrence of death” days within administration.
The study period is 180 days after vaccination with the “risk period” defined as 10 days after vaccination and the “control period” 11 to 180 days after vaccination.
Reported deaths occurred between 17 February 2021 and 12 March 2023; “Group 1” are those aged 65 years and over and “Group 2” are those 64 years and younger.
At a glance, most deaths occur on day 2 and day 3 after vaccination for Group 1, and most deaths occur on day 3 and day 4 for Group 2.
For Group 1:
Risk period deaths are 448 and 485 for male and female respectively, a total of 933.
Control period deaths are 214 and 164 for male and female respectively, a total of 378.
Therefore, 71.17% of deaths occurred in the risk period.
For Group 2:
Risk period deaths are 116 and 57 for male and female respectively, a total of 173.
Control period deaths are 39 and 35 for male and female respectively, a total of 74.
Therefore, 70.04% of deaths occurred in the risk period.
Given such a difference between the risk period and the control period, something is obviously not right. There may be other factors but it is difficult to deny the so-called vaccine as a cause.
The study compares the sex ratio between the risk period and the control period for all-cause mortality and eighteen other causes including “unexplained”. Although there isn’t necessarily a significant difference for all the conditions, there is for all-cause mortality. Table 2 for Group 2 is reproduced below.
In other words:
If there is no effect on the occurrence of death, there should be no difference in sex ratios by period. Thus, this finding indicates that vaccination may influence the occurrence of death during the risk period and might be associated with death.
Be sure to subscribe to our mailing list so you get each new Opinyun that comes out!
